Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tremfya Filed for Crohn’s Disease in Japan: J&J
Janssen Pharmaceutical, now operating under the brand of Johnson & Johnson Innovative Medicine, said on August 9 that it has filed its human anti-IL-23 monoclonal antibody Tremfya (guselkumab) for a label expansion into Crohn’s disease in Japan. The application was…
To read the full story
Related Article
- MHLW Panel Clears New Drugs from MSD, Pfizer, Amicus for Approval
June 5, 2025
- Pfizer’s UC Drug, MSD’s PAH Therapy, and More Up for Panel Review on June 4
May 22, 2025
- J&J Files Tremfya SC Induction Regimen for UC in Japan
March 7, 2025
- Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
BUSINESS
- Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
- Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
- Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
- GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
- Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…